FORT MILL, S.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a medical device company specializing in advanced electrophysiology solutions, today announced a surge in hospital evaluations and approvals for its LockeT suture retention device. As the company enters the first quarter of 2026, it reports significant progress in domestic and international product adoption, driven by successful clinical outcomes and the device's ability to streamline hospital workflows. Follo ...

FORT MILL, S.C., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced receipt of a LockeT purchase order from Universitätsklinikum Frankfurt (Frankfurt University Hospital). This purchase order marks the official entry of LockeT into Germany. The purchase order includes the LockeT suture retention device, a state-of-the-art solution ...

Expands Global Footprint to 15 CountriesFORT MILL, S.C., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced receipt of a VIVO purchase order from University Clinical Center Ljubljana, a leading hospital in Slovenia. This expands Catheter Precision’s global sales footprint to 15 countries. The University Clinical Center Ljubljana i ...

Core Viewpoint - Catheter Precision, Inc. has secured its first purchase order and a multi-year commitment for its LockeT device at Mater Private Hospital, Ireland's largest electrophysiology center, marking a significant step in the company's global expansion strategy and commitment to enhancing cardiac care safety and efficiency [1][4]. Group 1: Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians to advance electrophysiology procedures [6]. - The LockeT device is a suture retention device designed to assist in wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA and has received CE Mark approval [5]. Group 2: Product Implementation - The implementation of LockeT at Mater Private Hospital involved a rapid onboarding process, with the chief nurse training 52 staff members in just two days, highlighting the device's intuitive design and operational efficiency [3]. - Mater Private Hospital performs over 1,000 electrophysiology procedures annually, making it a crucial institution for arrhythmia treatment and innovation in Europe [2]. Group 3: Strategic Importance - The partnership with Mater Private Dublin is viewed as a major achievement for Catheter Precision, validating the technology and strengthening its position in the global electrophysiology market [4]. - The acceptance of LockeT at this hospital underscores the company's focus on expanding its international market presence and promoting technologies that enhance clinical outcomes [4].

Core Insights - Catheter Precision, Inc. has successfully launched its LockeT suture retention device in Switzerland, marking a significant milestone for the company in the cardiac electrophysiology market [1][2] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, particularly through advancements in electrophysiology procedures [4] Product Launch and Clinical Outcomes - The first clinical cases of the LockeT device were performed at Spitalzentrum Biel, led by PD Dr. Rainer Zbinden, resulting in excellent procedural outcomes and positive feedback from clinical and nursing teams [2] - The LockeT device is designed to assist in wound closure after percutaneous venous punctures and is classified as a Class 1 device registered with the FDA, also having received CE Mark approval [3] Strategic Partnerships - The launch follows a strategic distribution agreement with FuMedica AG, a prominent Swiss medical device distributor, which will facilitate the introduction of LockeT to hospitals and clinics across Switzerland, thereby expanding Catheter Precision's European presence [2][3] Market Growth - Over 10,000 LockeT devices have been shipped globally, indicating rapid growth and the company's commitment to working closely with partners to enhance patient care [3]

Core Insights - Catheter Precision, Inc. is positioned to expand the commercialization of its LockeT device following the recent addition of key electrophysiology (EP) ablation procedures to the ambulatory surgery centers (ASC) by the Centers for Medicare and Medicaid Services (CMS) [1][2] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias and advancing electrophysiology procedures through collaboration with physicians [5] Product Information - The LockeT device is a suture retention device designed for wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA and has received CE Mark approval [4] Industry Impact - The addition of EP ablation codes to the ASC-Covered Procedures List (ASC-CPL) by CMS, effective January 1, 2026, significantly enhances Medicare beneficiary access to EP services, marking a major advancement in the delivery of EP care in over two decades [2] Market Opportunity - The new CMS codes will facilitate additional patient scheduling and allow for the use of LockeT in more facilities, supporting physicians and patients in post-ablation recovery while ensuring cost-effectiveness and safety [3]

Core Insights - Catheter Precision, Inc. has achieved rapid commercial uptake of its LockeT closure device in South Africa, indicating strong market demand for its product [1][2]. Group 1: Product Implementation - The LockeT device was successfully implemented in five hospitals within two months, with three hospitals using it daily and two using it routinely [2]. - All five hospitals have placed reorders for the LockeT device through the local distributor, HLC Medical [2]. Group 2: Market Importance - The swift adoption of LockeT highlights its significance in emerging markets, where cost-effectiveness and improved workflow are critical [3]. - LockeT is designed to enhance patient care by enabling rapid hemostasis, which allows for same-day discharge [3]. Group 3: Product Overview - LockeT is a suture retention device intended for wound closure after percutaneous venous punctures and is classified as a Class 1 device registered with the FDA, also holding CE Mark approval [4]. Group 4: Company Background - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, emphasizing collaboration with physicians to advance its products [5].

Financial Highlights - Total revenue for Q3 2025 was reported at $226,000, marking a 135% increase from $96,000 in Q3 2024 [9] - For the nine months ended September 30, 2025, total revenue reached $581,000, up 114% from $271,000 in the same period of 2024 [9] - GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction compared to $4,120,000 in Q3 2024 [9] - GAAP net loss for the nine months ended September 30, 2025, was $11,405,000, compared to $11,015,000 for the same period in 2024 [9] Commercial Highlights - Sales activities for the LockeT device outside the U.S. are increasing, with CE Mark approval generating interest in countries such as Germany, France, Italy, Spain, Portugal, the UK, and South Africa [2] - In October, five accounts in South Africa placed reorders for LockeT [2] - VIVO product line is gaining traction internationally, with the first purchase order from France received in October [2] Clinical Studies and Publications - Clinical studies and publications remain a priority, with an interview in EP Lab Digest highlighting the economic benefits of the LockeT device for venous closure after electrophysiology procedures [3] Company Outlook - The CEO of Catheter Precision expressed confidence in a pivotal growth period ahead, supported by a well-established pipeline and the completion of two VIVO clinical studies in 2025 [4] - The company anticipates a major expansion of its approved product lines across U.S. and international markets [4] - VIVO is positioned as a transformative approach to treating ventricular arrhythmias, potentially capturing a significant share of an underserved market [4]

Core Insights - Catheter Precision, Inc. has entered into a strategic distribution agreement with FuMedica AG to introduce its LockeT suture retention device in Switzerland [1][4] - The LockeT device is designed to simplify and secure the closure of vascular access sites after cardiac procedures, enhancing procedural outcomes [2][5] - FuMedica AG is recognized for its excellence in distributing advanced medical technologies, particularly in cardiology, making it a suitable partner for Catheter Precision [3][7] Company Overview - Catheter Precision is a U.S.-based medical device company focused on innovative solutions for cardiac arrhythmias and electrophysiology procedures [6] - The company aims to improve treatment outcomes through collaboration with physicians and continuous product advancement [6] Product Details - The LockeT device is classified as a Class 1 medical device registered with the FDA and has received CE Mark approval, indicating its compliance with European health standards [5] - Its intuitive design and reliable performance have made it a valuable tool in electrophysiology labs and interventional suites globally [2] Partnership Significance - The agreement with FuMedica AG is a key milestone in Catheter Precision's European growth strategy, leveraging FuMedica's market knowledge and commitment to quality [4] - The partnership reflects Catheter Precision's dedication to global collaboration and innovation in cardiac care [4]

Core Insights - Catheter Precision, Inc. has received its first European purchase order for its product LockeT, marking a significant milestone in its market expansion efforts [1][3] - The successful evaluation of LockeT in Italy follows its acceptance in France and Germany, indicating strong clinical value and versatility [2][4] - The product is designed to assist in wound closure after percutaneous venous punctures and has received both FDA registration and CE Mark approval [4] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias, particularly in the electrophysiology market [5] - The company collaborates with physicians to continuously advance its product offerings [5] Product Details - LockeT is a suture retention device aimed at streamlining closure after catheter ablation procedures while being cost-effective [4] - The device is classified as Class 1 and is registered with the FDA, having also received CE Mark approval [4]